CTOs on the Move

Reset Therapeutics

www.resettherapeutics.com

 
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body`s network of internal molecular clocks. The circadian system synchronizes behavioral and physiological processes, including sleep, metabolism, feeding, blood pressure and hormone secretion with the environmental cycles of light, activity and nutrient status. Disruption of normal circadian rhythms is associated with many diseases, including central nervous system, cardiovascular and metabolic disorders, immune system dysfunction and cancer. Novel therapies that reset the body’s biological clocks have the potential to benefit very large and diverse patient populations
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Reset Therapeutics raised $29.73M on 02/19/2016

Similar Companies

Elabscience

Elabscience is a biotech corporation that specializes in laboratory reagents for life science research, including ELISA kits, FCM antibodies, biochemical kits, antibodies, and proteins.

Learn to Live CBT

Learn to Live offers online therapy programs for Stress, Depression and Social Anxiety based on the proven principles of Cognitive Behavioral Therapy (CBT).

AlphaRx

AlphaRx, Inc. is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NascoHealthcare

Nasco Healthcare simulation for healthcare training solutions ensures frontline heroes are READY in any situation. 5-year warranty and 100% made in the US.

Monte Rosa Therapeutics

Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.